<DOC>
	<DOCNO>NCT00377897</DOCNO>
	<brief_summary>This study treat cell therapy 20 patient critical leg ischemia ( CLI ) eligible revascularization angioplasty . It use exactly protocol publish Tateishi-Yuyama et al . ( Lancet 2002 ) , use bone-marrow mononuclear cell ( BMMNC ) .</brief_summary>
	<brief_title>Cell Therapy With Bone Marrow Mononuclear Cells Critical Leg Ischemia ( CLI )</brief_title>
	<detailed_description>Patients include CLI accord TASC criterion . Under general anesthesia , 500 ml bone marrow harvest iliac crest . After isolation concentration BMMNC 30 ml , 40 injection around 0.75 ml do gastrocnemius ischemic leg , within 3 hour preparation cell therapy product . Patients followed-up every week one month every month one year . This study approve ethical committee Paris-Broussais HEGP ( France ) french regulatory agency ( AFSSAPS ) . It begin include patient January 2005 last December 2007 .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Age &gt; 18 Signature inform consent Critical leg ischemia ankle pressure &lt; 70 mmHg Ischemic ulcer gangrene No possibility surgical revascularization No possibility angioplasty Cancer Suspicion cancer XRay , mammography elevate PSA Age &lt; 18 Life expectancy &lt; 6 month Active retinopathy Angioplasty surgical revascularization within 3 month Stoke within 3 month HIV + HCV/HBC+</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>critical leg ischemia</keyword>
	<keyword>PAD</keyword>
	<keyword>cell therapy</keyword>
</DOC>